BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BC Week In Review | Jun 29, 2009
Clinical News

Trofex: Phase I data

Data from a single-blind, crossover, U.S. Phase I trial in 5 patients with metastatic prostate cancer showed that a pair of radiolabeled small molecules, MIP-1072 and MIP-1095, detected metastatic tumors with similar target to background...
BC Week In Review | Jan 5, 2009
Clinical News

Molecular Insight preclinical data

In human prostate cancer cells, MIP-1072 demonstrated high affinity and specific binding to prostate-specific membrane antigen ( PSMA ). MIP-1072 and MIP-1095, a fellow radio-labeled molecular imaging agent targeting PSMA, are in a Phase I trial...
BC Week In Review | Jan 5, 2009
Clinical News

Molecular Insight preclinical data

In human prostate cancer cells, MIP-1095 demonstrated high affinity and specific binding to prostate-specific membrane antigen ( PSMA ). MIP-1095 and MIP-1072 , a fellow radio-labeled molecular imaging agent targeting PSMA, are in a Phase I trial...
BC Innovations | Jul 24, 2008
Tools & Techniques

Imaging Prostate Cancer Metastasis

Determining the status of lymph node metastasis in prostate cancer is important for deciding treatment options, but current techniques for detecting metastasis are imprecise and invasive. A paper published in Nature Medicine describes a noninvasive...
BC Week In Review | Jun 16, 2008
Clinical News

Trofex: Phase I started

Molecular Insight began a single-blind, crossover, U.S. Phase I trial to evaluate a pair of radiolabeled small molecules, MIP-1072 and MIP-1095, in up to 12 patients who have evidence of recurrent metastatic prostate cancer. The...
BC Week In Review | Mar 4, 2002
Clinical News

Xanelim anti-CD11a: Phase III

Pooled data from 1095 patients in 2 Phase III trials showed that 29% and 28% of patients treated for 12 weeks with 1 mg/kg and 2 mg/kg of Xanelim, respectively, had a 75% PASI improvement...
Items per page:
1 - 7 of 7